Aktieselskabet Schouw & Co.
9.2.2026 13:00:00 CET | Globenewswire | Press release
Schouw & Co. share buy-back programme, week 6 2026
Schouw & Co. share buy-back programme, week 6 2026
On 2 January 2026, Schouw & Co. initiated a share buy-back programme as outlined in Company Announcement no. 59 of 18 December 2025. Under the programme, Schouw & Co. will acquire shares for up to DKK 240 million during the period 2 January to 31 December 2026.
The buy-back will be structured in accordance with Regulation (EU) No. 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (MAR) and the Commission’s delegated regulation (EU) 2016/1052 of 8 March 2016 (“Safe Harbour” rules).
| Trading day | No. of shares | Average price | Amount DKK | ||
| Accumulated until 30 January 2026 | 52,500 | 670.98 | 35,226,452 | ||
| Monday, 2 February 2026 | 1,300 | 662.23 | 860,900 | ||
| Tuesday, 3 February 2026 | 1,300 | 673.84 | 875,998 | ||
| Wednesday, 4 February 2026 | 1,300 | 674.00 | 876,200 | ||
| Thursday, 5 February 2026 | 1,300 | 674.31 | 876,600 | ||
| Friday, 6 February 2026 | 3,583 | 685.17 | 2,454,955 | ||
| In the period 2 February 2026 - 6 February 2026 | 8,783 | 676.84 | 5,944,653 | ||
| Accumulated until 6 February 2026 | 61,283 | 671.82 | 41,171,105 | ||
| Following the above transactions, Schouw & Co. holds a total of 2,304,076 treasury shares corresponding to 9.22% of the total share capital of 25,000,000 shares. | |||||
Aktieselskabet Schouw & Co.
Jørgen Dencker Wisborg, Chairman
Jens Bjerg Sørensen, President, telephone number +45 86 11 22 22
Attachments
Documents
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Lakefront Biotherapeutics24.8.2026 22:01:00 CEST | Press release
Lakefront Receives Transparency Notification from Bank of America
Lakefront Biotherapeutics24.8.2026 22:01:00 CEST | Press release
U.S. FDA Grants Orphan Drug Designation to Gamgertamig for the Treatment of Pemphigus
Cosmos Health Inc.24.8.2026 21:40:00 CEST | Press release
Cosmos Health Projects Over $6M in Annual Revenue and $4.3M in Gross Profit from Oliv18™ Across the U.S. Cardiovascular Health and Antioxidant Categories
Kitron ASA24.8.2026 17:07:52 CEST | Press release
Kitron revises full-year 2026 outlook upwards
Zealand Pharma24.8.2026 17:05:00 CEST | Press release
Zealand Pharma – Notification of holding of treasury shares
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom